NEW YORK (GenomeWeb News) – The Institute for Systems Biology and AB Sciex today announced a partnership aimed at the development of a new mass spectrometry workflow.
Under the terms of the deal, ISB will use the AB Sciex TripleTOF 5600 mass spec system and Eksigent ekspert nano-LC 400 system to identify and quantify proteins as the institute further develops Swath Acquisition, a mass spec workflow that can quantify "virtually all detectable peptides and proteins in a complex sample — all in a single analysis," AB Sciex said.
Rainer Blair, president of AB Sciex, which was acquired by Danaher a few years ago, said in a statement, "What ISB does with Swath will set a new benchmark in proteomics research. Our collaboration with ISB will help drive Swath into the mainstream of analytical science and make comprehensive reproducible and simplified 'omics data more accessible to biologists around the world."
AB Sciex formed the collaboration with Leroy Hood, Robert Moritz, and others at ISB through the AB Sciex Academic Partnership Program, which seeks to increase the availability of new technologies to 'omics scientists.
Developing Swath is part of ISB's P4 medicine concept to develop medical care that is predictive, personalized, preventive, and participatory.
"Quantifying enormous numbers of protein analytes at the same time is a critical need to accelerate P4 medicine and the democratization of proteomics, a revolution that is akin to the sequencing of the genome and the democratization of DNA," Hood, the president and co-founder of ISB, said in a statement. "Swath is a game-changing technique that essentially acts as a protein microarray and is the most reproducible way to generate comprehensive quantitation of the entire proteome."
Swath libraries will be generated and made available to the scientists globally for biological research. Moritz, who is ISB Proteomics Research Director, will direct efforts to develop new Swath technologies and tools to accelerate the adoption of comprehensive quantitative proteome analysis, AB Sciex said.
Financial and other terms of the agreement were not disclosed.